The findings are consistent with prior research showing that counties lacking these services have poorer CV outcomes.
In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback